Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27423912 | 0.94 | CA2 (0.48) | CA2POLBIDO1MMP1MMP7 | |
| SCHEMBL11690780 | 0.87 | PTGS2 (0.55) | CA2POLBMMP8MMP12MMP13 | |
| SCHEMBL12821019 | 0.86 | POLB (0.58) | CA2POLBALDH1A1MAOBMEN1 | |
| SCHEMBL5609865 | 0.85 | POLB (0.56) | CA2POLBMAOAMAOBMEN1 | |
| SCHEMBL293747 | 0.83 | CA2 (0.55) | CA2IDO1MMP1MMP7MMP8 | |
| SCHEMBL12040646 | 0.83 | POLB (0.55) | CA2POLBMAOBMEN1KMT2A | |
| SCHEMBL12040620 | 0.83 | POLB (0.55) | CA2POLBMAOBMEN1KMT2A | |
| SCHEMBL15695395 | 0.82 | CA2 (0.50) | CA2POLBIDO1MMP1MMP7 | |
| SCHEMBL29434663 | 0.81 | MMP12 (0.53) | CA2MMP8MMP12MMP13CA12 | |
| SCHEMBL17929077 | 0.80 | ALDH1A1 (0.48) | CA2POLBIDO1CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866277-B1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2014-06-25 | — | — | EP | claimed |
| US-20110281879-A1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-7893093-B2 | Sulfonyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-02-22 | — | — | US | claimed |
| JP-4452441-B2 | — | — | 2010-04-21 | — | — | JP | claimed |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-11-20 | — | — | US | claimed |
| EP-1866277-A2 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | claimed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | claimed |
| WO-2006102535-A2 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | claimed |
| EP-1303487-A4 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2005-11-23 | — | — | EP | claimed |
| JP-2004513881-A | — | — | 2004-05-13 | — | — | JP | claimed |
| EP-1303487-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | Schering Corporation (US) | 2003-04-23 | — | — | EP | claimed |
| WO-2002008187-A9 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2003-01-03 | — | — | WO | claimed |
| US-20020160962-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME LLC | 2002-10-31 | — | — | US | claimed |
| WO-2002008187-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | claimed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| EP-4269543-A2 | POLYSILOXANE HYDRAULIC FLUIDS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2023-11-01 | — | — | EP | disclosed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| US-4523013-A | 4-Acyl-2,6-dioxo-1-phenethyl piperozines | SANOFI, S.A. (FR) | 1985-06-11 | — | — | US | disclosed |
| EP-0086678-A1 | Process for the preparation of 2-acyl-1,3,4,6,7,11b-2H-hexahydro-4-pyrazino(2,1-a)isoquinolinones and intermediates | ELF SANOFI (FR) | 1983-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281879-A1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | CA2 528/4885POLB 4029/4885IDO1 4285/4885 |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | CTSS, CTSF, CTSB | CA2 528/4885POLB 4029/4885IDO1 4285/4885 |
| US-20020160962-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, HPN, HAVCR2 | CA2 4312/4885POLB 4321/4885IDO1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.